Dominik Schumacher, Tubulis CEO

Bris­tol My­ers deep­ens ADC pipeline in $1B+ biobuck pact with Mu­nich start­up

Most of the an­ti­body-drug con­ju­gate talk late­ly has been cen­tered around Pfiz­er’s $43 bil­lion deal with Seagen, but Bris­tol My­ers Squibb is look­ing to up …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.